Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Goodwill (2017 - 2025)

Historic Goodwill for Adma Biologics (ADMA) over the last 9 years, with Q3 2025 value amounting to $3.5 million.

  • Adma Biologics' Goodwill changed 0.0% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $3.5 million for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, Adma Biologics' Goodwill stood at $3.5 million, which was down 0.0% from $3.5 million recorded in Q2 2025.
  • Adma Biologics' Goodwill's 5-year high stood at $3.5 million during Q4 2022, with a 5-year trough of $3.5 million in Q1 2021.
  • Moreover, its 5-year median value for Goodwill was $3.5 million (2021), whereas its average is $3.5 million.
  • As far as peak fluctuations go, Adma Biologics' Goodwill changed by 0.0% in 2021, and later increased by 1.39% in 2022.
  • Over the past 5 years, Adma Biologics' Goodwill (Quarter) stood at $3.5 million in 2021, then grew by 0.01% to $3.5 million in 2022, then changed by 0.0% to $3.5 million in 2023, then changed by 0.0% to $3.5 million in 2024, then changed by 0.0% to $3.5 million in 2025.
  • Its Goodwill was $3.5 million in Q3 2025, compared to $3.5 million in Q2 2025 and $3.5 million in Q1 2025.